

The Effects of Trans-Resveratrol on Insulin Resistance, Inflammation, and  
Microbiota in Men with the Metabolic Syndrome:  
A Pilot Randomized, Placebo Controlled Clinical Trial

Jeanne M. Walker, RN, MSN, ANP-C,<sup>1</sup> Patricia Eckardt, RN, PhD.,<sup>1</sup> Jose O. Aleman, MD,  
PhD,<sup>2,3</sup> Joel Correa da Rosa, PhD.,<sup>1</sup> Yupu Liang, PhD.,<sup>1</sup> Tadasu Iizumi, MD, PhD.,<sup>3</sup>  
Stephane Etheve,<sup>4</sup> Martin J. Blaser, MD,<sup>3</sup> Jan L. Breslow, MD,<sup>2</sup>  
and Peter R. Holt, MD, Senior Author <sup>2</sup>

<sup>1</sup> *The Rockefeller University Hospital, Rockefeller University, New York, New York, 10065;* <sup>2</sup>*Laboratory of Biochemical Genetics and Metabolism, Rockefeller University, New York, New York, 10065;* <sup>3</sup> *New York University School of Medicine, Department of Medicine, New York, New York; 10016.* <sup>4</sup>*DSM Nutritional Products LTD, Kaiseraugst, Switzerland*

Corresponding Author: Jeanne M. Walker, RN, MSN, ANP-C, The Rockefeller University Hospital, 1230 York Avenue, Box 317, New York, N.Y. 10065. 212-327-7270  
[walkerj@rockefeller.edu](mailto:walkerj@rockefeller.edu).

## **Abstract**

**Background and Aim:** The metabolic syndrome (MetS) is a pathological condition comprised of abdominal obesity, insulin resistance, hypertension and hyperlipidemia. It has become a major threat globally, resulting in rapidly increasing rates of diabetes, coronary heart disease and stroke. The polyphenol resveratrol (RES) is believed to improve glucose homeostasis and insulin resistance by activating sirtuin, which acetylates and co-activates downstream targets and affects glucose and lipid homeostasis in the liver, insulin secretion in the pancreas, and glucose uptake in skeletal muscle. We studied the effects of RES on insulin resistance, glucose homeostasis and concomitant effects on adipose tissue metabolism and fecal microbiota in insulin resistant subjects with the metabolic syndrome.

**Methods:** Twenty-eight obese men with the metabolic syndrome were studied during a 35-day stay in the Rockefeller University Hospital metabolic unit. Subjects were randomized to receive resveratrol 1 gram orally twice daily or placebo, while kept weight stable and consuming a Western style diet. At baseline, and after 30 days of resveratrol or placebo administration, subjects underwent testing that included a euglycemic, hyperinsulinemic clamp, 2- hour oral glucose tolerance test, resting energy expenditure (REE), daily blood pressure monitoring, abdominal adipose tissue biopsy, and fecal and blood collections.

**Results:** RES induced no changes in insulin resistance, but reduced the 120-minute time point and the area under the curve for glucose concentration in the two-hour glucose tolerance test (GTT). In post hoc analysis, Caucasian subjects showed a significant improvement in insulin sensitivity and glucose homeostasis after GTT, whereas non-Caucasians showed no similar effects. Levels of fasting plasma RES and its primary metabolite dihydroresveratrol (DHR) were

variable, and did not explain the racial differences in glucose homeostasis. RES administration to Caucasian subjects lead to an increase in several taxa including *Akkermansia mucinophila*.

**Conclusions:** Resveratrol 2 grams administered orally to obese men with metabolic syndrome and insulin resistance marginally altered glucose homeostasis. However, in a small group of Caucasians, insulin resistance and glucose homeostasis improved. No concomitant changes in adipose tissue metabolism occurred, but fecal microbiota showed RES-induced changes.

**Relevance for patients:** The metabolic syndrome increases the risk of diabetes, heart disease and stroke. A major component of the syndrome is insulin resistance, resulting in systemic inflammation and hyperinsulinemia. The primary treatment consists of lifestyle changes, improved diet and increased physical activity. This is often unsuccessful. In this study, RES was well tolerated. In Caucasian men it significantly improved insulin sensitivity and glucose homeostasis. Similar results were found in studies that consisted exclusively of Caucasian men. However, RES presents a novel addition to the current treatment of the MetS and its sequelae.

*Key words:* metabolic syndrome, euglycemic hyperinsulinemic clamp, insulin resistance, resveratrol, dihydroresveratrol, fecal microbiota, *Akkermansia mucinophila*, adipose tissue gene expression.

## 1. Introduction

The metabolic syndrome (MetS) is defined by central obesity, pre-diabetes, (insulin resistance), lipid disorders and hypertension. MetS is associated with an increased risk for cardiovascular disease, diabetes, and cancer [1]. About one-third of the adult U.S. population has the MetS, and prevalence increases with age [2-3]. Compared to adults 20-39 years of age, those 40-59 years of age were three times as likely, and those over the age of 60, were six times as likely to have MetS [3]. With aging of the population, the incidence of this condition is expected to rise markedly.

Insulin resistance is a central component of the MetS and is associated with obesity in which the hormone signaling cascade is diminished in adipose tissue and skeletal muscle. The liver fails to decrease glucose production in the presence of hyperglycemia, and lipid stores are released from adipose tissue. This reduction in insulin action results in increased inflammation which contributes further to the insulin resistance [4]. Insulin resistance sets the stage for progression to diabetes by increasing the demand on pancreatic beta cells to produce insulin, eventually exhausting the insulin supply.

In this study we examine the effects of trans-resveratrol (RES) [*3,5,4'-trihydroxy-trans-stilbene*], a natural product extracted from Japanese knotweed [5], peanuts, grapes, and certain berries [6], on insulin resistance in obese men with the MetS. RES dietary intake is very low, estimated to be only about 100µg/day from dietary intake,[7]. RES can act as a polyphenolic sirtuin (SIRT1) activator to acetylate and activate or deactivate many substrates, including Forkhead transcription factor and peroxisome proliferator-activated receptor (PPAR)- $\gamma$  by transactivating the coactivator PGC-1 $\alpha$  [8]. This is accompanied by effects on both glucose and

lipid metabolism. SIRT1 is expressed highly in many tissues including muscle, pancreas, and adipose tissues. Thus RES, as a natural activator of SIRT1, has the capacity to greatly affect nutrient metabolism. Fat deposition can be inhibited and pancreatic  $\beta$  cells protected from cytokine induced damage [9]. Specifically, RES has been reported to improve glucose tolerance and insulin resistance in rodents, [10] and humans [11]. In patients with cardiovascular disease, RES has been reported to reduce inflammation, as demonstrated by decreased circulating inflammatory markers such as C-reactive protein, IL-1 and IL-6 [12]. In humans, RES was also found to significantly suppress postprandial glucagon responses [13], contributing to improved insulin sensitivity. In a meta-analysis evaluating 11 studies involving 388 diabetic subjects, Liu et al., [14], found that RES, significantly reduced fasting glucose, insulin, hemoglobin A1C, and insulin resistance as measured by the homeostatic model assessment (HOMA). In patients with cancer, RES decreased oxidative stress and inflammation, through targeting of TANK-binding kinase 1 (TBK1), which is activated in many chronic inflammatory diseases [15].

RES can be modified by microbiota principally present in the colon, leading to transformation of several metabolic products [16]. Furthermore, in mice, RES can alter the gut microbiota with important metabolic effects, including reducing fat stores, thereby decreasing obesity [17]. RES also can alter the formation of trimethylamine-*N*-oxide (TMAO), through remodeling of the microbiota and inhibition of bile acid synthesis. This reduction of TMAO by RES may decrease development of atherosclerosis and coronary heart disease [18]. RES administration has been accompanied by changes in subcutaneous and visceral adipose tissues in rodents [19-20].

The primary hypothesis of our study was to determine if high dose RES, administered to obese men with insulin resistance and the MetS, would improve insulin sensitivity, glucose

tolerance, and other features of the MetS, and thus possibly contribute to established therapies of the disease. Secondary aims were to determine whether RES-induced changes in the MetS were accompanied by concomitant changes in gene expression of adipose tissue and on gut microbiota, as determined in the feces. Previous clinical trials of RES have shown improvement in one of the components of the MetS as discussed above. To our knowledge, this is the first human study to determine the effects of the RES on obese men with the MetS, under stable metabolic conditions in a randomized, placebo controlled trial.

## **2. Materials and Methods:**

### **2.1 Subjects:**

Subjects were recruited from the surrounding community through advertisements in local newspapers, on-line, and from the Rockefeller University subject repository. Eligible subjects were obese men (BMI 30-40kg/cm<sup>2</sup>) with insulin resistance determined by euglycemic, hyperinsulinemic clamp (i.e.  $M \leq 6.5$ mg/kg/minute), between the ages of 30-70 years, and three other features of the metabolic syndrome. These features included fasting blood glucose  $\geq 100$ mg/dl, serum triglycerides  $>150$  <500mg/dl, HDL cholesterol  $\leq 40$ mg/dl, waist circumference  $\geq 102$ cm, and blood pressure  $\geq 130$  mmHg systolic or  $\geq 85$  mmHg diastolic without medication, using NCEP ACP III 2005 criteria [21]. Exclusions were current smokers, subjects taking statins and medications metabolized by cytochrome p450 3A, elevated liver enzymes, diabetes, (fasting blood glucose  $>125$ mg/dl or hemoglobin A1C  $>6.5\%$ , or current diagnosis of diabetes), HIV infection, or abnormal thyroid function. Subjects gave written informed consent using Good Clinical Practice guidelines. The study was approved by the Institutional Review Board (IRB) and the Advisory Committee for Clinical and Translational Science (ACCTS) at The Rockefeller University (Protocol JWA-0786), and was registered with Clinical Trials.gov. # NCT01714102.

Sixty-one subjects were screened; thirty-one met the enrollment criteria and were randomized 1:1 by the research pharmacist before entering the study (Figure1). Due to the complexity and time required of the clamp procedure, the baseline clamp was performed as the final screen of the study, with subjects in the hospital to have it performed. Subjects understood, prior to enrolling, that they might be disqualified based on the result of the clamp. Withdrawn was one subject who left due to housing problems, one was withdrawn due to poor venous

access, and one left due to unrelated illness. The remaining 28 subjects completed the 35-day study, 14 randomly assigned to each group (Figure 1). Eleven subjects were Caucasian and 17 were non-Caucasian (13 African Americans, 3 Black Hispanics, 1 African American/Asian). This single-center study was performed at The Rockefeller University Hospital between October 2012 and September 2015.

## ***2.2 Design and Setting***

This was a double-blind pilot randomized parallel group design placebo controlled study. Subjects initially were screened in the Outpatient Research Center at the Rockefeller University Hospital (RUH), where they met with the study principal investigator J.W. Screening procedures comprised of a complete history and physical exam, fasting blood testing, resting energy expenditure, and waist measurements.

Eligible subjects were randomized by the research pharmacist in a 1:1 ratio using a web based randomization program, to receive either resveratrol or placebo. The study team and subjects were blinded as to the randomization to avoid bias. Subjects were admitted to the Rockefeller University inpatient metabolic unit for 35 days. They were fed for four days with an isocaloric Western style diet, (50% carbohydrate, 15% protein, 35% fat consisting of 13% saturated fat, 13% monosaturated fat, 7% polyunsaturated fat) [22]. Calories required to keep weight stable were determined by the resting energy expenditure data, a three day food diary, and subject's reported activity level. Developed by the Bionutrition Department, the diet included minimal amounts of resveratrol-containing foods. On Day 4, insulin sensitivity was measured by the euglycemic hyperinsulinemic clamp procedure. Insulin resistant subjects (defined as  $M \leq 6.5 \text{ mg/kg/min}$ ) completed the remaining baseline testing, which included blood tests (complete blood count, electrolytes, liver function tests, blood urea nitrogen, creatinine, and

C-reactive protein), 75 gram, two-hour oral glucose tolerance test, resting energy expenditure, waist measurement, daily BP monitoring, abdominal subcutaneous adipose tissue aspiration biopsy, fecal collection, and serum collection for insulin and lipids.

After baseline testing, subjects began receiving either two 500mg Mega-Resveratrol 99% capsules (made exclusively from organically grown Japanese knotweed root) or two 500mg placebo capsules, twice daily (Candlewood Stars, Danbury, CT) for 30 days, administered by the nursing staff. Only the research pharmacist was aware of the study drug allocation. The RES and placebo capsules were identical, placed in the medication cart by the pharmacist, and administered to the patients by registered nurses in identical packaging. Since RES is photosensitive [23], the product was stored in dark bottles. The measured RES content of the capsules was 524 mg each, so that the total daily dose administered was actually 2096 mg. Body weight was monitored each morning in a hospital gown, and maintained within 1.5% of baseline weight by adjusting caloric intake as needed. Subjects consumed an isocaloric, Western style diet, and no other foods or drinks were permitted. Subjects slept in the hospital where they always consumed breakfast and dinner, and were provided with a packed lunch on days they did not have testing. On non-testing days they were permitted to leave the hospital to work, or to pursue other interests. Daily activity was monitored by a New Lifestyles NL-800 accelerometer (New Lifestyles, Lee's Summit, MO). Safety blood laboratory tests and EKG testing were monitored. After 30 days of consuming the study drug or placebo, baseline testing was repeated.

### ***2.3 Procedure Methods***

***Anthropometric measurements:*** Body weight was measured daily, using a Scale-Tronix 5002 scale (Welch Allyn, Skaneateles Falls, N.Y.) with a precision of +/- 0.1kg. Subjects were weighed in a hospital gown, after an overnight fast and post voiding. Height was measured at

baseline with a Seca-216 stadiometer (Hamburg, Germany) in 1 mm increments. Body mass index (BMI) was calculated as weight/height squared ( $\text{kg}/\text{m}^2$ ), using the NIH Standard Metric BMI calculator.

**Daily blood pressure monitoring:** Manual blood pressure readings (Welch Allyn aneroid monitor, Skaneateles Falls, N.Y.) were taken by the hospital staff each morning and recorded. The mean of the systolic and diastolic readings taken on the four mornings of baseline testing was statistically compared with the mean of the systolic and diastolic readings measured on the final four days of the study.

**Resting energy expenditure:** (On Day 7 and 35) Resting energy expenditure was determined by indirect calorimetry using a Viasys Vmax Encore Calorimeter (Cardinal Health, Yorba Linda, Cal).

**2 hour oral glucose tolerance test:** (On Day 6 and 34) A fasting 75 gram oral glucose tolerance drink was administered, and serum glucose and insulin levels were determined at -10, -5, 0, 30, 60, 90, and 120 minutes. HOMA-IR scores were calculated from the 0 timepoint data. ( $\text{Insulin } \mu\text{IU}/\text{ml}(\text{mU}/\text{l}) \times \text{Glucose } (\text{mg}/\text{dl})$ ).

**Abdominal fat biopsy aspiration:** (On Day 7 and 35) Subcutaneous abdominal aspiration biopsy of white adipose tissue was performed under local anesthesia, using a 4mm liposuction needle, for gene expression analysis.

**Euglycemic hyperinsulinemic clamp:** (On Day 4 and 32) Euglycemic hyperinsulinemic clamp was performed infusing  $80\text{mU}/\text{m}^2/\text{min}$  Humulin R (Lilly, Indianapolis, IN). Glucose levels were monitored every 5 minutes using the YSI 2300 STAT Plus Glucose and Lactate Analyzer

(Yellow Springs, OH.). Plasma glucose was maintained between 90-100mg/dl by titration of intravenous 20% Dextrose solution (Baxter Healthcare, Deerfield, Ill.) infusion.

***Fecal Microbiome analysis:*** Fresh fecal samples were obtained in the hospital, from seven placebo treated and nine RES-treated subjects, and samples were kept frozen at -80° C until analysis. Permission to study fecal samples in the remaining subjects could not be obtained.

Fecal DNA was extracted from 20mg aliquots of feces using the PowerSoil DNA Isolation Kit (QIAGEN, Germantown MD) according to the manufacturer's protocol. Purified DNA from stool samples was amplified by PCR using the 16S rRNA V4-region primers (515F/806R) using the Earth Microbiome Protocol. Amplified DNA samples were quantified using the Picogreen kit (Qiagen), and were pooled at equimolar ratios. Samples were then purified by PCR purification kit (Qiagen). Samples were multiplexed with unique barcodes and sequenced with 150-bp paired end reads (2 x 150) on the MiSeq 2500 platform.

***Qiime analysis:*** The forward and reverse paired-end reads were joined using the *fastq-join* command from EA-utils. Reads with a minimum overlap of 30nt and with perfect matching of bases between reads, were de-multiplexed, and analyzed by Qiime software (Qiime 1.9.1). After reads were filtered for base-pairs with Phred score > 20, sequences were clustered into operational taxonomic units (OTUs) using an open-reference approach with UCLUST against the Greengenes database (13\_8 release), using PyNAST. ANOVA tests of OTU and genus-level abundances were performed in QIIME. A rarefaction analysis was accomplished for Chao-1 and whole PD (phylogenetic diversity) to measure alpha diversity. Unweighted UniFrac distances were calculated to assess beta diversity. The unweighted pair group method with arithmetic mean (UPGMA) was performed for UniFrac-based jackknifed hierarchical clustering. Principal coordinates analysis (PCoA) was performed by calculating UniFrac distance matrices, and KiNG

was used for graphical representation. Linear discriminant analysis (LDA) effect size (LEfSe), a tool that can compare differences of relative abundance between two or more biological conditions was used for analysis of the results [24]. PICRUSt (Phylogenetic Investigation of Communities by Reconstruction of Unobserved States) was used to predict the metagenomic content from the 16S rRNA sequencing data, and KEGG pathway functions were categorized at level 3 [25].(Langille, et al., 2013).

***Plasma resveratrol (RES) and its primary metabolite dihydroresveratrol (DHR) levels*** were determined in the laboratory of DSM Nutritional Products Limited, Kaiseraugst, Switzerland, before and after 30 days of resveratrol administration. To determine free RES, an internal standard (resveratrol-phenyl-13C6) was added to an aliquot of plasma followed by a liquid-liquid extraction. For conjugated RES forms, a digestion with  $\beta$ -glucuronidase was performed after addition of an internal standard, followed by liquid-liquid extraction. After centrifugation, an aliquot of the organic phase was evaporated to dryness, re-dissolved in injection solvent and analyzed. Quantitation was achieved by use of internal standards and an external standard calibration curve. Samples were analyzed by LC-MS/MS in negative electrospray mode, validated according to the bioanalytical method EMEA and FDA validation guidelines.

***Analysis of Mega-Resveratrol 500mg capsule:*** After extraction, RES was analyzed by RP-HPLC-UV applying an isocratic method with a phosphate buffer as mobile phase and the detection wavelength of 305 nm. Quantification was carried out using trans-resveratrol as external standard, by a validated method.

***RNA Sequencing of Abdominal White Adipose Tissue:*** Abdominal subcutaneous adipose tissue biopsies were analyzed by RNA SeQ. Total RNA was extracted from approximately 0.5 g of frozen adipose tissue using a Qiagen RNeasy Lipid Tissue Mini Kit (Germantown, MD). RNA

quality was assessed using an Agilent Bioanalyzer. Approximately 2 to 3 mg of RNA with RNA integrity number 0.7 were submitted. Twenty one subjects consented to RNA sequencing of the adipose tissue, six did not give consent for analysis, and one subject did not undergo the biopsy due to anxiety. Adipose tissue from before and after treatment from 10 RES-treated and 11 placebo-treated subjects were referred for 50-bp paired-end read RNA sequencing polyA-enriched RNA at The Rockefeller University Genomics Research Center. Of those on RES, five were Caucasians and five were non-Caucasians. Gene expression was analyzed for pathway enrichment using Gene Set Enrichment Analysis (GSEA; Broad Institute, Cambridge MA) and Ingenuity Pathway Analysis (Qiagen).

The FASTQ files were first quality controlled through FastQC v0.11.15 [26]. Cutadapt v1.9.1 was used to locate and remove the adapter sequences from each high-throughput sequencing reads before mapping [27], as applied to trim the low quality bases and TrueSeq adapters ( times =2; quality-base =33; quality-cutoff =5; format =FASQT; minimum-length =25 –a AAAAAAAAAAAAAA TTTTTTTTTTTTTT –a AGATCGGAAGAG –a CTCTTCCGATCT). Trimmed FASTQ files were aligned to the human genome (GRCH37) using STAR v.2.4.2 [28], aligner with default parameters. The alignment results were then evaluated through Qualimap v.2.2 [29], to ensure that all the samples had a consistent coverage, alignment rate, and no obvious 5' or 3' bias. Aligned reads were then summarized through feature Counts v1.5, [30]. The gene model used for this purpose was that from Ensembl at gene level. The uniquely mapped reads (NH 'tag' in bam file) that overlapped with an exon (feature) by at least 1bp were counted, and then the counts of all exons annotated to an Ensembl gene (meta features) and were summed into a single number. edgeR\*v.3.16.5 [31], was used to normalize the samples, and

Voom from limma # v.3.30.11 was applied to estimate the differential log fold change in the expression of genes.

### ***Adipose Tissue Pathway Enrichment Analysis***

A linear mixed-effects model as implemented in R limma package was applied to analyze differences in gene expressions from pre- to post-treatment. Moderated t-statistics were used for testing hypotheses about differential expression. The genes were ranked according to the magnitude of their significance, determined by the false discovery rate (FDR)  $p < 0.05$ . The ranked genes list was submitted to enrichment analysis in the GSEA software. The normalized enriched scores were tested for statistical significance and the gene sets with  $FDR < 0.05$  were reported as significantly associated with changes from pre- to post-resveratrol administration. This same procedure was used for a subgroup analysis that included only Caucasians.

### **3. Statistical Analysis**

In this double-blind pilot randomized parallel group design placebo-controlled study, the one-sided hypothesis was that resveratrol reduces insulin resistance in obese, weight-stable men with the metabolic syndrome. The primary outcome was the euglycemic hyperinsulinemic clamp measured at Day 30 of study. Secondary outcomes included insulin resistance (OGTT), systolic and diastolic BP, triglycerides, circulating inflammatory markers in serum and adipose tissue, and gene expression in adipose tissue measured at the same time points as primary outcome. In addition, the effects of RES upon fecal microbiota composition and imputed metagenomic functions were determined.

### ***3.1 Data Protection and Management***

Unblinded, coded data was downloaded from a secure server, exported from REDCap to csv. format, and imported into IBM SPSS 19. Coded data and associated syntax and output files were maintained on a secure double-password protected desktop. Transfer of coded data was behind institutional firewall via encrypted email. Less than 1% of data was found to be missing, so that subsequent analyses proceeded.

### ***3.2 Power Analysis and Sample Size***

Based on preliminary data from prior, unpublished studies, when randomization results in equivalent distribution of confounders across groups, the low variability of clamp results suggests extremely small sample sizes through the use of traditional power calculations. If one creates 14 matched pairs based on known risk factors, the risk of at least 10 of the more insulin-resistant subjects being in one group and at most five of the more insulin-resistant subjects in the other group (i.e., a 2:1 confounder ratio, or worse) is below 20% and the risk for a 1:5 ratio is below 5%. However, if there is more than one confounder, and the confounders are at least partially independent, the resultant ratio may be less. Given the accuracy of the clamps, and the exploratory nature of this study, a sample size of 14 subjects in each group provides balance for comparison of study outcomes. Potential confounders and baseline data were found not to be significantly different between groups (Table 2). Randomization therefore resulted in homogeneous groups.

### ***3.3 Comparison of effects of the treatment groups on primary and secondary outcomes.***

The effects of the intervention on the primary and secondary outcomes were compared. The primary outcome of the analysis, the clamp data after 30 days, was compared between the two groups using a Wilcoxon/Mann-Whitney test. The remaining outcomes were tested for

normal distribution within the groups, and independent sample two-tailed t-tests were conducted to test hypotheses that resveratrol had a positive effect (i.e. reduction) on the primary and secondary outcomes.

### ***3.4 Comparison within subjects of primary and secondary outcomes***

Individual baseline data on the primary and secondary outcomes had been collected on all subjects allowing for estimates of changes from pre- to post- treatment within subjects, in addition to between the two treatment groups, on all outcome variables. Change scores were calculated for each subject on primary and secondary variables, using general linear models. Specifically, analyses of covariance (ANCOVA) were conducted on outcomes with premeasures of the same variable (e.g., baseline GTT 120 minute time point, baseline clamp, baseline mean systolic blood pressure). Group assignment was a fixed factor within the model.

### ***3.5 Comparison of demographics on primary and secondary outcomes based on post intervention outcomes***

To examine the large within-group subject variance, individual patient trajectories were graphed over time. Sub-patient populations were constructed blocked on race, ethnicity, and age. The means and variance for each subgroup were plotted and compared between groups for significance.

## 4. Results

### 4.1 Metabolic Components:

Of 61 subjects screened, 31 were found eligible and were entered into the study. Three subjects were withdrawn, so that 28 subjects completed the study, and 14 subjects were randomized to each group (Figure 1). The resveratrol preparation was tolerated well, and measures of plasma RES levels demonstrated that RES subjects were compliant. At baseline, features characteristic of the metabolic syndrome did not differ between the RES and placebo-treated groups (Table 1). Study subjects were all class 1-2 obese with similar ages and resting energy expenditure (REE) (Table 2). There was no evidence of any increase in inflammatory markers such as white blood count (WBC) and high sensitivity C-reactive protein (hsCRP).

Following 30 days of RES treatment, there were no significant differences in the measures that characterized the metabolic syndrome between the RES and placebo treated groups (Table 3A). The insulin clamp measure of insulin resistance did not differ between the RES and placebo treated, nor did serum insulin and HOMA measures (Table 3B). However, the 120 minute glucose concentration in the RES treated subjects was significantly lower than in placebo subjects ( $p=0.023$ ), and the area under the curve for glucose levels during the glucose tolerance test was marginally lower ( $p=0.05$ ). No other end point measures differed between the groups. With the a priori significance level of 5%, differences between groups reached statistical significance on multiple outcomes when mean values were compared between groups (Table 4).

In a post hoc analysis of covariance (ANCOVA) to control for baseline data, (Table 4A), we observed a difference between the treatment groups (RES vs placebo) when divided into Caucasian and non-Caucasian subjects, in the effects of RES on glucose homeostasis and race. As shown in Table 4B, there were highly significant effects on insulin resistance as measured by

the insulin clamp technique in Caucasian when compared to non-Caucasian subjects ( $p < 0.001$ ). Furthermore, the 120 minute end-point glucose level and the glucose concentration area under the curve during the glucose tolerance test were significantly lower in Caucasian subjects (Table 4B). At baseline, these two groups did not differ in age, BMI or the number of components of the metabolic syndrome (Data not shown).

Since these group differences in glucose homeostasis could have resulted from differences in RES absorption, distribution or metabolism, we measured fasting level of RES and its primary metabolite, dihydroresveratrol (DHR), in all study subjects. The overall data in the total 14 RES treated subjects varied greatly between subjects (Table 6). There were no differences between Caucasian and non-Caucasian subjects in plasma concentrations of RES and DHR. We also determined potential correlations between plasma concentrations of RES and DHR and the MetS components, adipose tissue gene expression, and fecal microbiota, and found no significant correlations (Data not shown).

#### ***4.2 Adipose Tissue:***

To determine changes with RES treatment that may influence glucose metabolism, abdominal subcutaneous adipose tissue biopsies were analyzed by RNA SeQ and by GSEA enrichment analysis. After correction for multiple comparisons, no significant changes in individual gene expression and gene expression pathways between biopsies taken before and after the study in placebo treated subjects were detected. Correcting for multiple comparisons, there also were no significant differences between RES and placebo treated subjects at the end of the study.

To gain further insight into possible effects of RES intervention on adipose tissue gene expression for subsequent, more detailed study, we evaluated a selection of the top individual

genes that were altered in the RES intervention group of subjects (Table 7). Upregulated gene expression occurred with the RAB 40A member of the RAS oncogene family, microRNA 192, apolipoprotein C4, a growth differentiation factor, a member of the TNF 2 receptor superfamily, the 5-hydroxytryptamine receptor1B , two olfactory receptors, and 32 long, intergenic non-protein coding RNAs. We found no significantly downregulated genes by RES treatment. Contrary to expectations, genes related to sirtuin and mTOR pathways did not change.

By GSEA analysis, the three Caucasian subjects were negatively enriched with the TGF beta signaling gene expression pathway compared to the five non- Caucasians in whom adipose tissues were available for analysis.

#### ***4.3 Comparison of intestinal bacterial communities in the placebo and RES treatment groups.***

Fecal samples were available for study from seven Caucasian and nine non-Caucasian subjects. Nine subjects (3 Caucasians and 6 non-Caucasians) received RES. In these subjects, both alpha-diversity as measured by Phylogenetic diversity (PD), and community structure as measured by beta diversity, changed significantly over the course of the study, but as expected, no significant differences developed in the placebo-treated controls.(Figure 2). The community structure did not differ significantly pre-treatment between the 2 groups, but differed post-treatment ( $p= 0.01$ ). The data showed that species richness (alpha-diversity, as measured by Phylogenetic diversity (PD)), fell over the course of the study in the total of 16 subjects in whom specimens were available, but not significant differences in the community structure (beta differences as measured by UniFrac distances).

Next, we asked whether individual taxa showed significant changes in relative abundance in the RES and the placebo groups (Figure 3). In placebo controls, there were no significant differences in the taxa comparing the pre- and post-treatment specimens. However, several taxa

changed significantly in the RES subjects with a fall in *Rikenellaceae*, *Ruminococcus*, *Oscillospira*, *Clostridium*, *Alistipes*, *Odoribacter*, and *Butyricimonas*, and a rise in *Gammaproteobacteria*, *Gemellaceae*, *Turicibacter*, and *Atopobium*.

In the PICRUS<sub>t</sub> comparative analysis of imputed biochemical pathways in the metagenome (Figure 4), placebo treated subjects again showed no significant differences, whereas the RES group showed decreases in pathways related to ribosomal translation, aminoacyl tRNA biosynthesis, apoptosis, carotenoid biosynthesis, and cysteine and methionine metabolism. Post-RES treatment, the dominant pathways were glutathione metabolism, ion transport and metabolism, pertussis, biotin metabolism, and fatty acid metabolism.

Since we found several differences in glucose tolerance and insulin resistance between the Caucasian and non-Caucasian RES treated subjects, we examined changes in fecal microbiota corresponding to these individuals. There were no significant differences in either alpha or beta diversity between Caucasian and non-Caucasian subjects. (Data not shown). However, LEFSe showed significant taxonomic differences between these two groups. In the Caucasians, *Alistipes*, *Collinsiella*, *Christensenella*, *Holdemania*, and *Turicibacter* were among the taxa that fell during the treatment, and *Bilophila* rose (Figure F1). In non-Caucasians, *Ruminococcaceae*, *Alphaproteobacteria*, *Christensenella*, *Odoribacter* and *Clostridium* were taxa that fell during treatment, while *Proteobacteria* rose (Figure F2.). In pre-study Caucasians, there was significant over-representation of *Collinsella*, *Clostridiaceae*, and *Ruminococcus*, but *Streptococcus*, and *Lactobacillales* were over-represented in the non-Caucasians (Figure F3). Post treatment, the Caucasian subjects showed significantly higher levels of *Akkermansia mucinophila*, *Fusobacteria*, and *Megamonas*, compared to the non-Caucasians (Figure F4).

## 5. Discussion

This double blind, placebo controlled study of a large dose of resveratrol (2 grams daily), did not show a significant effect on insulin sensitivity or on glucose homeostasis, by our primary endpoint of euglycemic hyperinsulinemic clamp, when compared to the placebo treated group of subjects. Glucose homeostasis was marginally affected as measured by glucose tolerance test. The placebo and RES groups did not differ in factors contributing to the metabolic syndrome or other potentially important end point variables. Our essentially inconclusive results agree with a five week cross-over study of resveratrol 1 gm. per day in diet-controlled diabetic subjects [32]. Furthermore, this is consistent with a placebo-controlled study of resveratrol 150 mg or 1 gm. per day in moderately obese, but otherwise healthy community-living men [33], as well as a study by Poulsen, et al., [34] which used resveratrol 1.5 gm. per day in obese subjects and failed to improve insulin resistance.

These studies contrast with earlier studies in which resveratrol 1-2 gm. per day was provided to older subjects with impaired glucose tolerance who showed modest improvement in insulin resistance estimated from the Matsuda index [11] and a 3 month open label study of resveratrol 250 mg. per day in patients with type 2 diabetes taking oral antidiabetic medications [35]. Crandall, in an editorial, wondered whether resveratrol would be effective only when glucose homeostasis was clinically impaired [36]. Korshalm et al. [37] agrees, observing that subjects with modest insulin resistance are optimal to determine effects of RES on insulin resistance, but that healthy individuals are not affected by RES due to normal glucose homeostasis. In addition, longer studies may be necessary to determine the effect of RES on chronic conditions such as insulin resistance and low-grade inflammation.

It has been stated that there is sufficient information from rodent studies that RES has the capacity to improve insulin sensitivity and reduce blood glucose levels accompanied by modulation of inflammatory response to various stimuli. RES has been used in conjunction with metformin to improve insulin sensitivity and glucose homeostasis in pre-diabetic subjects [38]. However, studies in humans are fragmentary and generally inadequate [39].

Unexpectedly, when we performed a post-hoc analysis of the several factors that could have influenced our data, including the effects of race, the Caucasian subjects showed a highly significant effect of RES on glucose homeostasis, with reduction in insulin resistance, and a decline in both the 120-minute glucose concentration and the area under the curve in the oral glucose tolerance test, whereas non-Caucasian subjects had no significant effects on these measures. However, the dispersion of the non-Caucasian subjects' 120-minute glucose concentration and the area under the curve was greater than the Caucasian subjects, which could decrease the likelihood of significant finding within the non-Caucasian subjects.

These differences could have reflected variation in RES absorption, known to be inconsistent [16], or in RES distribution and metabolism. Our current data on fasting plasma concentration of RES and its primary metabolite dihydroresveratrol (DHR), did not explain the difference in glucose homeostasis with RES administration in the Caucasian subjects. We recognize that our study was powered for our primary outcome, a change in insulin resistance, and not for the secondary outcomes. This poses the potential that a type 2 error might have occurred in the analysis of the secondary outcomes.

---

Our data contrasts with a Dutch comprehensive metabolic study of 11 grade 1 obese healthy men without MetS and mean 26% body fat, who were administered RES in a dose of 150mg/day for 30 days in a placebo controlled, cross-over study [40]. These authors reported

that RES reduced resting metabolic rate, muscle inflammation, and intramyocellular lipid content. The RES-treated group in this study also showed reductions in fasting serum glucose, triglycerides, leptin, insulin, and HOMA, as well as several circulating markers of inflammation. The reasons for the differences between our results and their data are unclear. It is of interest that the subjects in the Timmers study were all Caucasians (personal communication) and thus, their improvement with RES may have paralleled the data in our Caucasian subjects. The RES dose of 150 mg/day and the fasting plasma levels of RES and DHR in the Timmers' study were much lower than those measured in our study. Lower concentration effects might reflect an inverted U effect. Further studies of RES administration to obese or metabolic syndrome Caucasians and non-Caucasian subjects seem warranted.

We included studies of subcutaneous white adipose tissue gene expression, since adipose tissue dysfunction is common in obese subjects, and RES might improve inflammation in fat tissues. Although we found no significant changes in the expression of genes and gene pathways in adipose tissue after correction for multiple factors, the selection of the individual genes that were most upregulated by RES included two olfactory genes. Several olfactory receptor genes in adipose tissue have been reported to modulate increased fat mass in obesity [41]. In rodents fed a high fat controlled diet, resveratrol 30 mg/kg body weight was shown to reduce body weight, fat mass and white adipose tissue lipolytic activity [42]. Others have described downregulation of the mTOR pathway [10, 20], and in inflammatory markers [19], after RES administration. These data differ from our null findings in human subcutaneous adipose tissue. In contrast, in another human study, RES at a dose of 150mg per day for 30 days in obese men was reported to reduce adipocyte size associated with regulation of genes linked with cell cycle regulation, and lysosomal activity, suggesting stimulation of an alternative pathway of lipid metabolism [43].

The reasons for the discrepancy between the two studies are unclear, but this data was taken from subjects in the cross-over metabolic study by Timmers discussed previously.

Increasing evidence has focused on the role of the gut microbiota in determining the metabolism of drugs and certain over-the-counter supplements [44]. Furthermore, drugs and supplements can alter the composition and the function of the microbiota in the gut [45].

Although RES has been shown to affect the gut microbiome *in vitro*, and in rodents *in vivo*, [46], these data are not consistent across studies. A comprehensive metabolomic analysis on blood, urine, adipose tissue, and skeletal muscle tissue in middle-aged men with metabolic syndrome randomized to receive either resveratrol or placebo treatment for four months, found the composition of the gut microbiota was altered by RES treatment, with reduction in sulfated androgen precursors in blood, adipose tissue and muscle, increasing these metabolites in the urine. [37].

The microbiome may also affect the metabolism of RES [47]. The principal metabolite is DHR, but further molecular changes include glucuronidation and sulfation [46], which occurs in the gastrointestinal tract and the liver. A detailed *in vitro* study of the effects of the gut microbiota on RES showed that the major RES metabolite resulting from gut microbial action was dihydroresveratrol (DHR) and indoxy metabolites, including the formation of lumularin [16].

In the panel of microbes used for these *in vitro* studies, *Slakia equolifaciens* and *Adlercreutzia equolifaciens* were the principle producers of DHR. In mice, RES 200mg/kg/d, was shown to improve gut microbial dysbiosis as measured by increased *Lactobacillus* and *Bifidobacterium* species, and reduced *Enterococcus faecalis* [17]. *Lachnospiraceae* often produce butyrate, a beneficial short chain fatty acid [48]. By inhibition of several commensal

microbiota, RES can attenuate the gut microbial metabolism of trimethylamine-*N*-oxide (TMAO) [18]. Indeed, in TMAO-fed Apo-E *-/-* mice, RES inhibited atheroma formation via changes in such gut microbiota accompanied by increased bile salt hydrolase deconjugation of conjugated bile salt acids.

In our study, RES reduced microbial diversity and led to several changes in individual microbiota. RES-treated Caucasian subjects who showed improvement in insulin sensitivity and glucose homeostasis, also had a significant increase in *Akkermansia mucinophila*, a microbe that, in experimental animals, has been inversely associated with obesity, diabetes and low grade inflammation [49]. Administration of a purified *A. mucinophila* membrane protein to mice also has improved insulin sensitivity and reduced fat mass [50], consistent with potential therapeutic efficacy.

Although other investigators have focused on the role of RES as a SIRT activator, we found no change in SIRT gene expression in adipose tissue. SIRT1 has been linked to both lipid and glucose homeostasis. In white adipose tissue, SIRT1 inhibited adipogenesis in precursor cells and reduced fat storage in differentiated cells [51]. SIRT1 can also regulate glucose homeostasis by altering different tissue targets. In pancreatic  $\beta$ -cells, SIRT1 is a positive regulator of insulin secretion and can protect  $\beta$ -cells against oxidative stress by deacetylation of FOX-0 proteins. In the liver, SIRT1 may regulate gluconeogenesis. In target tissue, SIRT1 may affect glucose homeostasis by modifying the responses of target cells to insulin, by regulating the activity of PGC-1 $\alpha$  [52].

In conclusion, we demonstrated only minor overall effects of the administration of RES in a dose of 2 grams per day to obese men with insulin resistance and the metabolic syndrome. However, post hoc analysis showed a significant improvement in insulin sensitivity and glucose

tolerance during a two-hour oral glucose tolerance test, in RES-treated Caucasian subjects. These improvements were not seen in non-Caucasians treated with RES. This observation was not explained by differences in RES absorption or metabolism as determined by measures of plasma concentrations of RES and its primary metabolite DHR, or by examining effects on adipose tissue gene expression. In fecal microbiome, RES altered alpha and beta diversity in treated subjects compared to placebo control subjects. Further studies of RES in Caucasian and non-Caucasian insulin resistant, obese subjects, are needed to confirm our finding and to seek functional explanation for these differences.

### **Acknowledgements**

This study was supported in part by a grant #**ULI TROO1866** from the National Center for Advancing Translational Sciences (NCATS, National Institutes of Health (NIH) Clinical and Translational Science Award (CTSA) program, to Rockefeller University, and **UL1-TR001445** to New York University Langone Medical Center, The Rockefeller University Center for Basic and Translational Research on Disorders of the Digestive System from the Leona M. and Harry B. Helmsley Charitable Trust, The Rockefeller University Sackler Center for Biomedicine and Nutrition from La Fondation Sackler, **R01 DK090989**, The Heilbrunn Women in Science Award through the generosity of The Heilbrunn Nurse Scholar Award.

**Conflict of interest disclosure:** The authors declare no conflicts of interest

## References

1. American Heart Association. About metabolic syndrome.  
[http://www.heart.org/HEARTORG/Conditions/More/MetabolicSyndrome/About - Metabolic- Syndrome\\_UCM\\_301920\\_Article.jsp#.Whs1fkqnFRY](http://www.heart.org/HEARTORG/Conditions/More/MetabolicSyndrome/About-Metabolic-Syndrome_UCM_301920_Article.jsp#.Whs1fkqnFRY)
2. Aguilar M, Bhuket T, Torres S, Liu B, Wong RJ. Prevalence of the metabolic syndrome in the United States, 2003-2013. *JAMA*. 2015; **313**(19):1973-1974.
3. Ervin RB. Prevalence of metabolic syndrome among adults 20 years of age and over by sex, age, race and ethnicity, and body mass index: United States, 2003-2006. *Natl Health Stat Report* 2009; **5**(13):1-8.
4. Johnson AR, Milner JJ, Makowski L. The inflammation highway: Metabolism accelerates inflammatory traffic in obesity. *Immunol Rev* 2012; **240**(1):218-238.
5. Chen H, Tuck T, Ji X, Zhou X, Kelly G, Cuerrier A, Zhang J. Quality assessment of Japanese Knotweed (*Fallopia japonica*) grown on Prince Edward Island as a source of resveratrol. *J Agric Food Chem*. 2013; **61**(26):6383-6392.
6. Wenzel E, Somoza V. Metabolism and bioavailability of trans-resveratrol. *Mol Nutr Food Res*. 2005; **49**(5):472-481.
7. Zamora-Ros R, Rothwell JA, Achanintre D, Ferrari P. Evaluation of urinary resveratrol as a biomarker of dietary resveratrol intake in the European Prospective Investigation into Cancer and Nutrition (EPIC) study. *Br J Nutr* 2017; **117**(11):1596-1602.
8. Lagouge M, Argmann C, Gerhart-Hines Z, Meziane H, Lerin C, Daussin F, Messadeq N, Milne J, Lambert P, Elliott P, Geny B, Laakso M, Puigserver P, Auwerx

- J. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1a. *Cell* 2006; **127**(6):1-14.
9. Frojdo S, Durand C, Pirola L. Metabolic effects of resveratrol in mammals: A link between improved insulin action and aging. *Curr Aging Sci.* 2008; **1**:145-151.
10. Bauer JA, Pearson KJ, Price NL. Resveratrol improves health and survival of mice on a high-calorie diet. *Nature* 2006; **444**(7117): 337-342.
11. Crandall J, Oram V, Trandafirescu G. Pilot study of resveratrol in older adults with impaired glucose tolerance. *J of Gerontol A Bio Med Sci* 2012; **67**(12):1307–1312.
12. Wahab A, Gao K, Jia C, Zhang F, Tian G, Murtaza G, Chen J. Significance of resveratrol in clinical management of chronic diseases. *Molecules* 2017; **22**(8):1329.
13. Knop FK, Konings E, Timmers S, Schrauwen P, Holst JJ, Blaak EE. Short report: Pathophysiology: Thirty days of resveratrol supplementation does not affect postprandial incretin hormone responses, but suppresses postprandial glucagon in obese subjects. *Diabet Med* 2013; **30**:1214-1218.
14. Liu K, Zhou R, Wang B, Mi MT. Effect of resveratrol on glucose control and insulin sensitivity: a meta-analysis of 11 randomized controlled trials. *Am J Clin Nutr* 2014; **99**(6):1510-9.
15. Singh CK, Ndiaye MA, Ahmad N. Resveratrol and cancer: Challenges for clinical translation. *Biochimica et Biophysica Acta*, (2014); 1852(6):1178-1185.
16. Bode LM, Bunzel D, Huch M, Cho GS, Ruhland D, Bunzel M, Bub A, Franz CM, Kulling SE. In vivo and in vitro metabolism of trans-resveratrol by human gut microbiota. *Am J Clin Nutr* 2013; **97**(2):477-479.

17. Qioa Y, Sun J, Xia T, Shi Y, Le G. Effects of resveratrol on gut microbiota and fat storage in a mouse model with high-fat-induced obesity. *Food Func* 2014; **5**(6):1241-1249.
18. Chen M, Yi L, Zhang Y, Zhou X, Ran L, Yang J, Zhu JD, Zhang QY, Mi M. Resveratrol attenuates trimethylamine-N-oxide (TMAO)-induced atherosclerosis by regulating TMAO synthesis and bile acid metabolism via remodeling of the gut microbiota. *mBIO* 2016; **7**(2):e02210-15.
19. Ding S, Jian J, Wang Z, Shang G, Yin J, Wang X, Wang S, Yu Z. Resveratrol reduces the inflammatory response in adipose tissue and improves adipose insulin signaling in high-fat diet-fed mice. *PeerJ* 2018; **6**:e5173.
20. Jung M, Lee J, Shin N, Kim M, Hyun D, Yun J, Kim P, Whon T, Bae J. Chronic repression of mTOR complex 2 induces changes in the gut microbiota of diet-induced obese mice. *Sci Rep* 2016; **6**(30887):1-10.
21. Huang PL. A comprehensive definition for metabolic syndrome. *Dis Model Mech* 2009; **2**(5-6):231-237.
22. Pendyala S, Walker JM, Holt PR. A high-fat diet is associated with endotoxemia that originates from the gut. *Gastro* 2012; **5**(142):1000-1101.
23. Amri A, Chaumeil JC, Sfar S, Charrueau C. Administration of resveratrol: What formulation solutions to bioavailability limitations? *J Control Release* 2011; **158**(2):182-193.
24. Segata N, Izard J, Waldron L, Gevers D, Miropolsky L, Garrett WS, Huttenhower C. Metagenomic biomarker discovery and explanation. *Genome Biol* 2011; **12**(6):R60.

25. Langille MGI, Zaneveld J, Caporaso JG, McDonald D, Knights D, Reyes JA, Clemente JC, Burkepile DE, Vega Thurber RL, Knight R, Beiko RG, Huttenhower C. Predictive functional profiling of microbial communities using 16S rRNA marker gene sequences. *Nat Biotechnol* 2013; **31**(9): 814-821.
26. Andrews S. (2010). FastQC: A quality control tool for high throughput sequence data. <http://www.bioinformatics.babraham.ac.uk/projects/fastqc>.
27. Martin M. Cutadapt removes adapter sequences from high-throughput sequencing reads. *EMBnet.j* 2011; **17**(1):10-12. <http://journal.embnet.org/index.php/embnetjournal/article/view/200/458>
28. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, Batut P, Chaisson M, Gingeras, TR. STAR: ultrafast universal RNA-seq aligner. *Bioinformatics* 2013; **29**(1):15-21.
29. Garcia-Alcalde F, Okonechnikov K, Carbonell J, Cruz LM, Gotz S, Tarazona S, Dopazo J, Meyer TF, Conesa A. QualiMap: Evaluating next-generation sequencing alignment data. *Bioinformatics* 2012; **28** (20): 2678-2679.
30. Lia Y, Smyth GK, Shi W. featureCounts: An efficient general purpose program for assigning sequence reads to genomic features. *Bioinformatics* 2014; **30**(7): 923-930.
31. McCarthy J.D, Chen Y, Smyth K.G. Differential expression analysis of multifactor RNA-Seq experiments with respect to biological variation. *Nucleic Acids Res* 2012; **40**(10):4288-4297.
32. Thazhath S, Wu T, Bound MJ, Checklin HL, Standfield S, Jones KJ, Horowitz M, Rayner CK. Administration of resveratrol for five weeks has no effect on glucagon-

- like peptide-1 secretion, gastric emptying or glycemic control in type 2 diabetes: A randomized controlled trial. *Am J Clin Nutr* 2016; **103**(1): 66-70.
33. Kjaer TN, Ornstrup MJ, Poulsen MM, Stodkilde-Jorgensen H, Jessen N, Jorgensen JOL, Richelsen B, Pedersen S.B. No beneficial effects of resveratrol on the metabolic syndrome: A randomized placebo-controlled clinical trial. *J Clin Endocrinol Metab* 2017; **102**(5):1642-1651.
34. Poulsen MM, Vestergaard PF, Clasen BF, Radko Y, Christensen LP, Stodkilde-Jorgensen H, Møller N, Jessen N, Pedersen SB, Jorgensen JOL. High-dose resveratrol supplementation in obese men: An investigator-initiated, randomized, placebo-controlled clinical trial of substrate metabolism, insulin sensitivity, and body composition. *Diabetes*, 2013; **62**(4): 1186-1195.
35. Bhatt JK, Thomas S, Nanjan MJ. Resveratrol supplementation improves glycemic control in type 2 diabetes mellitus. *Nutr Res* 2012; **32**(7):537–541.
36. Crandall JP, Barzilai N. Exploring the promise of resveratrol: Where do we go from here? *Diabetes* 2013; **62**(4): 1022-1023.
37. Korsholm AS, Kjaer TN, Ornstrup MJ, Pedersen SB. Comprehensive metabolomic analysis in blood, urine, fat, and muscle in men with metabolic syndrome: A randomized, placebo-controlled clinical trial on the effects of resveratrol after four months' treatment. *Int J Mol Sci* 2017; **18**(3): 1-19.
38. Frendo-Cumbo S, MacPherson REK, Wright DC. Beneficial effects of combined resveratrol and metformin therapy in treating diet-induced insulin resistance. *Physiol Rep* 2016; **4**(15):e12877; 1-12.

39. Vang O, Ahmad N, Baile CA, Baur JA, Brown K, Csiszar A, Das DK, Delmas D, Gottfried C, Lin HY, Ma QY, Mukhopadhyay P, Nalini N, Pezzuto JM, Richard T, Shukla Y, Surh YJ, Szekeres T, Szkudelski T, Walle T, Wu JM. What is new for an old molecule? Systematic review and recommendations on the use of resveratrol. *PLoS One* 2011; **6**(6) e19881: 1-11.
40. Timmers S, Konings E, Bilet L, Houtkooper RH, Van de Weijer T, Goossens GH, van der Krieken S, Ryu D, Kersten S, Moonen-Kornips E, Hesselink MKC, Kunz I, Schrauwen-Hinderling VB, Blaak E, Auwerx J, Schrauwen P. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. *Cell Metab* 2011; **14**(5): 612-622.
41. Wu C, Hwang SH, Jia Y, Choi J, Kim YJ, Choi D, Pathiraja D, Choi IG, Koo SH, Lee SJ. Olfactory receptor 544 reduces adiposity by steering fuel preference toward fats. *J Clin Invest* 2017; **27**(11): 4118-4123.
42. Alberdi G, Rodriguez VM, Miranda J, Macarulla MT, Arias N, Andres-Lacueva C, Portillo MP. Changes in white adipose tissue metabolism induced by resveratrol in rats. *Nutr Metab* 2011; **8**(29): 1-11.
43. Konings E, Timmers S, Boekschoten MV, Goossens GH, Jocken JW, Afman LA, Muller M, Schrauwen P, Mariman EC, Blaak, EE. The effects of 30 days resveratrol supplementation on adipose tissue morphology and gene expression patterns in obese men. *Inter J Obes* 2014; **38**(3):470-473.
44. Sharma AK, Jaiswal SK, Chaudhary N, Sharma VK. A novel approach for the prediction of species-specific biotransformation of xenobiotic/ drug molecules by the human gut microbiota. *Sci Rep* 2017; **7**(1):9751:1-13.

45. Koppel N, Rekdal VM, Balskus EP. Chemical transformation of xenobiotics by the human gut microbiota. *Science*, 2017; **356**(6344): 1-29.
46. Bird JK, Raiderstorff D, Weber P, Steinert RE. Cardiovascular and anti-obesity effects of resveratrol mediated through the gut microbiota. *Adv Nutr* 2017; **8**(6): 839-849.
47. Wilson ID, Nicholson JK. Gut microbiome interactions with drug metabolism, efficacy and toxicity. *Transl Res* 2017; 179:204-222.
48. Meehan CJ, Beiko RG. A phylogenomic view of ecological specialization in the *Lachnospiraceae*, a family of digestive tract-associated bacteria. *Genome Biol Evol* 2014; **6**(3):703-713.
49. Cani PD, deVos, WM. Next-generation beneficial microbes: The case of *Akkermansia mucinophila*. *Front Microbiol* 2017; **8**(1765):1-8.
50. Plovier H, Everard A, Druart C, Depommier C, Van Hul M, Geurts L, Chilloux J, Ottman N, Duparc T, Lichtenstein L, Myridakis A, Delzenne NM, Klievink J, Bhattacharjee A, van der Ark KCH, Aalvink S, Martinez LO, Dumas M, Maiter D, Loumaye A, Hermans MP, Thissen J, Belzer C, de Vos WM, Cani PD. A purified membrane protein from *Akkermansia mucinophila* or pasteurized bacterium improves metabolism in obese and diabetic mice. *Nat Med* 2016; **23**(1):107-113.
51. Gonzalez-Rodriguez A, Mas Gutierrez JA, Sanz-Gonzalez S, Ros M, Burks DJ, Valverde A. Inhibition of PTP1B restores IRS1-mediated hepatic insulin signaling in IRS2-deficient mice. *Diabetes* 2010; **59**(3): 588-599.
52. Guarente L. Sirtuins as potential targets for metabolic syndrome. *Nature* 2006;

444(7121):868-874.

53. Xia X, Weng J. Targeting metabolic syndrome: Candidate natural agents.

*J Diabetes* 2010; **2**(4): 243-249.

**Table 1**

**Baseline Metabolic Syndrome Characteristics of Subjects**

	<b>Placebo n=14</b>		<b>Resveratrol n=14</b>		
	<b>Mean+/-SD</b>	<b>CI 95%</b>	<b>Mean+/-SD</b>	<b>CI 95%</b>	<b>p=</b>
<b>FBG (mg/dl)</b>	104 +/- 22	92-117	98 +/- 12	91-105	0.322
<b>HDL (mg/dl)</b>	42 +/- 9	37-47	40 +/- 7	36-44	0.672
<b>TG (mg/dl)</b>	146 +/- 56	114-179	125 +/- 75	82-168	0.409
<b>SBP (mmHg)</b>	119 +/- 9	115-124	118 +/-6	115-121	0.717
<b>DBP (mmHg)</b>	77 +/-6	74-81	78+/-2	77-80	0.457
<b>Waist circ (cm)</b>	116 +/-8	111-120	117+/-11	111-123	0.813

**Comparison of the baseline metabolic syndrome characteristics of the total group of resveratrol and placebo treated subjects.**

*Terms: mg/dl=milligrams per deciliter; FBG=fasting blood glucose; HDL=high density lipids; TG=triglycerides; SBP=systolic blood pressure; DBP=diastolic blood pressure; mmHg=millimeters of mercury; cm=centimeter; waist circ=waist circumference*

**Table 2**

**Baseline Comparison of Subjects by Treatment**

	<b>Placebo n=14</b>		<b>Resveratrol n=14</b>		<b>p=</b>
	<b>Mean+/-SD</b>	<b>CI 95%</b>	<b>Mean+/-SD</b>	<b>CI 95%</b>	
<b>Clamp M (mg/kg/min)</b>	4.3 +/-0.9	3.8-4.8	4.4+/-1.3	3.7-5.2	0.705
<b>Insulin (mIU/l)</b>	14 +/-8	9-19	22+/-20	10-33	0.194
<b>HOMA (%)</b>	3.7 +/-2.3	2.3-5.0	5.5+/-6.3	1.8-9.1	0.322
<b>120 min data 2hr GTT(mg/dl)</b>	184 +/-58	151-218	153+/-24	139-167	0.081
<b>AUC (mg/dl)</b>	345 +/-77	301-389	310+/-41	286-333	0.145
<b>WBC (k/mcl)</b>	6.0 +/-1.4	5.2-6.8	6.0+/-1.6	5.1-6.9	0.960
<b>CRP (mg/dl)</b>	0.33 +/-0.17	0.24-0.43	0.58+/-0.34	0.39-0.78	0.734
<b>REE(k/cal/d)</b>	1778 +/-204	1652-1898	1754+/-209	1627-1880	0.789
<b>BMI(kg/m<sup>2</sup>)</b>	33.8 +/-3.3	32.0-35.7	35.0+/-3.0	33.2-36.7	0.317
<b>Age (years)</b>	47 +/-8	42-52	48+/-9	43-60	0.772

**Comparison of the baseline laboratory data, BMI and age of the total group of resveratrol and placebo treated subjects.**

*Terms: Clamp M=mg/kg/min of dextrose required to maintain plasma glucose at level of 90-100mg/dl during euglycemic hyperinsulinemic clamp; 120 min data = the blood glucose level at 120 minutes of a 2 hour oral glucose tolerance test; GTT: oral glucose tolerance test; AUC: area under the curve; HOMA: homeostatic model assessment, assesses insulin resistance and beta cell function; WBC: white blood cell count; CRP: C-reactive protein; TG= serum triglycerides; REE: resting energy expenditure; BMI: body mass index; CI=confidence interval.*

**Table 3A Post-Treatment Comparison of Metabolic Syndrome Characteristics of RES and Placebo Treated Subjects**

	<u>Placebo n=14</u>		<u>Resveratrol n=14</u>		
	<u>Mean+/-SD</u>	<u>CI 95%</u>	<u>Mean+/-SD</u>	<u>CI 95%</u>	<u>p =</u>
<b>FBG (mg/dl)</b>	104 +/-16	95-113	98 +/- 11	91.2-104	0.288
<b>HDL (mg/dl)</b>	41 +/- 8	37-46	40+/-8	36-45	0.664
<b>TG (mg/dl)</b>	130 +/-50	101-159	138+/- 86	86-188	0.762
<b>SBP (mmHg)</b>	120 +/-13	113-128	123+/-13	116 -131	0.476
<b>DBP (mmHg)</b>	79+/-6	75-82	81+/-5	78-84	0.207
<b>Waist circ(cm)</b>	115+/- 9	110-121	116 +/-10.4	110-122	0.860

**Table 3B** Post-Treatment Comparison of RES and Placebo Treated Subjects  
Placebo (n=14) Resveratrol (n=14)

	<u>Mean+/-SD</u>	<u>CI 95%</u>	<u>Mean+/-SD</u>	<u>CI 95%</u>	<u>p=</u>
<b>Clamp M (mg/kg/min)</b>	4.2+/-1.4	3.4-5.0	4.6 +/-1.8	3.6-5.6	0.525
<b>Insulin (mg/dl)</b>	17 +/-8	13-21	20+/-16	10-29	0.537
<b>HOMA(%)</b>	4.4+/- 2.2	3.1-5.7	5.0+/- 5.2	2.0-7.0	0.698
<b>120min data 2hr GTT (mg/dl)</b>	172 +/- 39	150-195	139+/-13	120-158	<b>0.023*</b>
<b>AUC (mg/dl)</b>	346+/- 64	309-383	304+/- 42	280-328	<b>0.050*</b>
<b>WBC (k/mcl)</b>	5.9+/- 1.3	5.1-6.7	5.2 +/-1.5	4.3-6.1	0.209
<b>CRP (mg/dl)</b>	0.40 +/- 0.20	0.28-0.52	0.60+/- 0.41	0.36-0.84	0.111
<b>REE(k/cal/d)</b>	1798+/-225	1662-1934	1778+/-228	1640-1976	0.821
<b>BMI(kg/m<sup>2</sup>)</b>	33.7 +/-3.3	31.8-35.6	34.9+/- 3.0	33.2-36.7	0.331

**Comparison of the post-treatment metabolic syndrome characteristics (3A) and laboratory data and BMI (3B) for the total group of resveratrol and placebo treated subjects.**

*Terms and units are the same as in Table 1 and 2.*

*\*p ≤ 0.05*

**Table 4A**

**Baseline Comparison of Significant Findings by Subject Race**

	<u>Caucasians (n=11)</u>		<u>Non-Caucasians (n= 17 )</u>		<b>p=</b>
	<b>Mean+/-SD</b>	<b>CI 95%</b>	<b>Mean+/-SD</b>	<b>CI 95%</b>	
<b>Clamp M</b>	3.9 +/-1.1	3.2-4.7	4.6 +/- 1.1	4.1-5.2	0.090
<b>120min data 2hr GTT (mg/dl)</b>	154 +/- 26	137-171	178 +/-55	150-206	0.192
<b>AUC (mg/dl)</b>	318 +/- 33	295-340	334 +/- 77	294-373	0.518

**Table 4B**

**Post-Treatment Comparison of Significant Findings by Race within Treatment Groups**

	<u>Placebo n=14</u>		<u>Resveratrol n=14</u>		<b>p=</b>
	<b>Mean+/-SD</b>	<b>CI 95%</b>	<b>Mean+/-SD</b>	<b>CI 95%</b>	
	<u>Caucasians (n=6)</u>		<u>Caucasians (n=5)</u>		
<b>Clamp M</b>	4.3 +/-1.5	2.7-5.9	4.9 +/-2.5	1.7-8.0	<b>&lt;0.001*</b>
<b>120min data 2hr GTT(mg/dl)</b>	163 +/- 26	136-191	132 +/- 24	102-162	<b>0.001*</b>
<b>AUC (mg/dl)</b>	350 +/-55	293-408	302+/- 29	266-339	<b>0.006*</b>
	<u>Non-Caucasians (n=8)</u>		<u>Non-Caucasians (n=9)</u>		
<b>Clamp M</b>	4.2 +/- 1.5	3.0-5.4	4.5 +/-1.4	3.4-5.5	0.940
<b>120min data 2hrGTT(mg/dl)</b>	179 +/- 47	140-218	143+/- 38	114-173	0.962
<b>AUC (mg/dl)</b>	344 +/-75	281-405	305 +/- 49	267-343	0.376

**Comparison of the baseline (4A) and post-treatment (4B) glucose tolerance and clamp M data in the Caucasian and non-Caucasian group of resveratrol and placebo treated subjects.**

*Terms and units are the same as in Table 2*

**Table 5**

**Baseline Comparison by Race in RES Treated Subjects (n=14)**

	<u>Caucasians (n=5)</u>		<u>Non-Caucasians (n=9)</u>		<b>p=</b>
	<b>Mean+/-SD</b>	<b>CI95%</b>	<b>Mean+/-SD</b>	<b>CI95%</b>	
<b>FBG (mg/dl)</b>	95+/-10	83.-107	102+/- 16	90-114	0.366
<b>HDL (mg/dl)</b>	37+/-3	33-40	41+/- 6	37-46	0.136
<b>TG (mg/dl)</b>	177 +/- 100	52-301	101+/- 38	72-130	0.170
<b>SBP (mmHg)</b>	117 +/-5	110-123	119 +/- 6	114-124	0.415
<b>DBP (mmHg)</b>	78 +/-3	74-82	80+/-2	78-81	0.233
<b>Waist circ (cm)</b>	121+/-12	108-135	115 +/- 10	107-122	0.258
<b>BMI (kg/m<sup>2</sup>)</b>	34.1+/-2.8	30.6-37.6	35.6 +/- 2.9	33.3-37.8	0.375
<b>Age (yrs)</b>	49 +/- 9	38-59	47+/- 9	41-54	0.785

**Comparison of the baseline characteristics and laboratory data of the Caucasian and non-Caucasian resveratrol treated subjects.**

*Terms and units are the same as in Table 1 and 2*

**Table 6 Plasma RES and DHR Levels Post RES Treatment (n=14)**

	<b>Caucasians (n=5 )</b>	<b>Non-Caucasians (n=9 )</b>	
	<b>Mean+/-SD</b>	<b>Mean+/-SD</b>	<b>p=</b>
<b>RES (nmol/L)</b>	23,203 +/- 8,467	27,349 +/-13,908	0.559
<b>DHR (nmol/L)</b>	2,276 +/- 3,411	5,709 +/-10,111	0.482

---

*Terms: RES nmol/L = resveratrol measured in nano-moles/liter*

*DHR nmol/L = dihydroresveratrol, the primary metabolite of resveratrol, measured in nano-moles/liter*

**Table 7**


**Post RES Selection of Altered Genes in Subcutaneous Adipose Tissue**


<b>Gene Symbol</b>	<b>Gene Designation</b>	<b>p Value</b>	<b>Log fold change</b>
<b>RAB40A</b>	<b>RAB40A member RAS oncogene family</b>	<b>0.00013</b>	<b>0.2715</b>
<b>FAM230C</b>	<b>Family with sequence similarity 230 member C</b>	<b>0.00026</b>	<b>0.2330</b>
<b>MIR192</b>	<b>micro-RNA 192</b>	<b>0.0012</b>	<b>0.2117</b>
<b>APOC4</b>	<b>Apolipoprotein C</b>	<b>0.0014</b>	<b>0.1934</b>
<b>MFAP2</b>	<b>Microfibrillar associated protein 2</b>	<b>0.0019</b>	<b>0.2434</b>
<b>GDF2</b>	<b>Growth differentiation factor 2</b>	<b>0.0027</b>	<b>0.2564</b>
<b>OR52E4</b>	<b>Olfactory receptor family 52, subfamily E, member 4</b>	<b>0.0031</b>	<b>0.1918</b>
<b>OR4D6</b>	<b>Olfactory family 4, subfamily D, member 6</b>	<b>0.0033</b>	<b>0.1820</b>
<b>TNFRSF13B</b>	<b>TNF receptor superfamily member 13B</b>	<b>0.0036</b>	<b>0.2052</b>
<b>HTR1B</b>	<b>5-hydroxytryptamine receptor 1B</b>	<b>0.004</b>	<b>0.2128</b>
<b>LINC00982</b>	<b>Long intergenic non-protein coding RNA 982</b>	<b>0.005</b>	<b>0.5994</b>
<b>LINC01356</b>	<b>Long intergenic non-protein coding RNA 1356</b>	<b>0.005</b>	<b>0.5141</b>

**Significantly altered gene expression data in adipose tissue following resveratrol treatment.**

Figure 1

TREND FLOW CHART





**Figure 2. Differences in fecal microbiota between the Resveratrol and Placebo-Control total subject groups.**

Upper panels:  **$\beta$ -diversity** as determined by unweighted UniFrac analysis;


Lower panels: Differences in  **$\alpha$ -diversity** between groups, left, Mean  $\pm$  SD; right, Median + IQR box and whisker (95%) CI.

**Plot color codes:**


Blue: **Placebo-Control** pre-treatment; Red: **Placebo-Control** post-treatment;

Green: **Resveratrol** pre-treatment; Light blue: **Resveratrol** post-treatment.

In RES treated subjects, significant changes were seen in alpha-diversity as measured by Phylogenetic diversity (PD) ( $p=0.01$ ), and community structure, as measured by beta diversity ( $p=0.007$ ). There were no changes in the placebo group pre and post treatment.



**Figure 3. LefSe Cladogram and LAD score of treatment differences.** Identification of significant taxonomic differences associated with the total Placebo-Control group (n=14 samples), and of the total Resveratrol group (red: pre-treatment, green: post-treatment) (n=18 samples). (Right) Histogram of the LDA scores was calculated for the most differential taxa with Resveratrol treatment.



**Figure 4. PIECRUST functional analysis of the control (placebo) and resveratrol treatments in the total subject group.** Analyses using functions imputed by the PICRUST algorithm, with score of LDA>2). Histogram of the LDA scores was calculated for the most abundant taxa altered by the **Resveratrol** treatment.

**Appendix Figure Legends for microbiota.**

**Supplemental Figure F1-4.**

**Identification of significant taxonomic differences by LEFSE within the Resveratrol treated**

**group.**  $n = 3$  Caucasian subjects and 6 non-Caucasian subjects. Bar graphs represent  $\log_{10}$  differences in LDA scores. All bars shown represent significant findings ( $p < 0.05$ )

(F1) Comparison between pre- and post-treatment samples in the Caucasian treated subjects.

(F2) Comparison between pre- and post-treatment samples in non-Caucasian treated subjects.

(F3) Comparison between Caucasian subjects and non-Caucasian subjects at baseline.

(F4) Comparison between Caucasian subjects and non-Caucasian subjects post-trial.

### Appendix- Supplemental Figures

Figure F1




Figure F2




Figure F3





Figure F4

Caucasian post vs  
Non-Caucasian post



Caucasian post

